US · Healthcare · Diagnostics & Research
EPS came in at 0.62 against a street estimate of 0.60 — a beat of 3.3%.
Analysts rate Qiagen NV a buy (9 buy, 7 hold, 0 sell out of 16) with an average price target of $47.80.
CONFIDENT QGEN beat Q2 outlook on sales and EPS, reaffirming full-year guidance. Growth pillars (Sample Tech +9%, QIAcuity double-digit, QDI solid) offsetting QuantiFERON immigration testing headwinds. H2 acceleration expected from new launches and easier comps. Q2 2026 Mixed regional performance; sequential improvement in China and ex-China Asia-Pacific gaining momentum. Analysts pressed on QuantiFERON tariffs, funding headwinds, and automation timelines. Management defended with TAM expansion, TST conversion thesis, and product validation justifying timelines; maintained strategic-review optionality without timeline. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| Wellington Management Company LLP | 6.01% |
| T. Rowe Price Associates, Inc. | 5.50% |
| Principal Financial Group Inc | 3.22% |
| Vanguard Capital Management, LLC | 3.01% |
| BlackRock Inc | 2.86% |
| Morgan Stanley - Brokerage Accounts | 2.44% |
| Earnest Partners LLC | 2.21% |
| The Goldman Sachs Group Inc | 2.15% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • QIAGEN appointed Jonathan M. Pratt as Chief Executive Officer, effective September 1, 2026. • Pratt has more than 25 years of lea | 2026-09-09 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 net sales were $535,040 thousand, up from $533,540 thousand in Q2 2025. • Q2 2026 net income was $103,401 thousand, up f | 2026-08-07 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 net sales were $535 million, unchanged from Q2 2025 on both reported and constant exchange rate (CER) bases, exceeding the | 2026-08-07 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • QIAGEN serves more than 500,000 customers in over 160 countries, with direct sales in over 40 countries. • The company employed a | 2026-08-07 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • QIAGEN filed its Form 20-F for the fiscal year ended December 31, 2025, reporting under U.S. GAAP. • The company had 216,920,735 | 2026-03-20 |
| Annual report FY2024 (20-F) | 2025-03-31 |
| Quarterly results (6-K) · Q1 2024 | 2024-05-01 |
| Annual report FY2023 (20-F) | 2024-03-11 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.35 / share ex-date Jul 7, 2026 · pay Jul 14, 2026 | 2026-07-07 |
| Dividend | $2.41 / share ex-date Jan 8, 2026 | 2026-01-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Qiagen NV — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.